Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRay GroupSHSE:688301 -2.07%95 ROE % is 12.77% as of Jun. 2026, which is 28% below its 10-year median of 17.77. GuruFocus rates SHSE:688301 with a GF Score™ of 95/100 and a GF Value™ of ¥109.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, iRay Group ranks better than 77.39% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. iRay Group's annualized net income for the quarter that ended in Jun. 2026 was ¥908 Mil. iRay Group's average Total Stockholders Equity over the quarter that ended in Jun. 2026 was ¥7,106 Mil. Therefore, iRay Group's annualized ROE % for the quarter that ended in Jun. 2026 was 12.77%.
The historical rank and industry rank for iRay Group's ROE % or its related term are showing as below:
SHSE:688301'
s ROE % Range Over the Past 10 Years
Min: 10.37 Med: 17.77 Max: 27.36
Current: 11.5
During the past 11 years, iRay Group's highest ROE % was 27.36%. The lowest was 10.37%. And the median was 17.77%.
SHSE:688301's ROE % is ranked better than 77.39% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 2.755
vs SHSE:688301: 11.50
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
iRay Group ROE % Related Terms
iRay Group ROE % Historical Data
* Premium members only.
The historical data trend for iRay Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, iRay Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRay Group ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRay Group's ROE % distribution charts can be found below:
* The bar in red indicates where iRay Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
iRay Group (SHSE:688301) has a ROE % of 12.77% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on iRay Group and its competitors. This is 28% below median its historical median of 17.77. Over the past decade, iRay Group's ROE % has ranged from 10.37 to 27.36. According to the industry distribution chart, iRay Group ranks #180 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 22.6%.
Is iRay Group's ROE % too high?
iRay Group's current ROE % of 12.77% is 28% below median its 10-year median of 17.77. Over the past 10 years, this metric has ranged from a low of 10.37 to a high of 27.36. The Medical Devices & Instruments industry median ROE % is 2.76. iRay Group's value of 12.77% is 363.5% above this industry median. Based on the distribution chart, iRay Group ranks #180 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRay Group has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRay Group's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, iRay Group ranks #180 out of 796 companies for ROE %. This places iRay Group in the top 23% of its industry — outperforming the majority of peers. The industry median ROE % is 2.76. iRay Group's value of 12.77% is 363.5% above this benchmark. Historically, iRay Group's own ROE % has ranged from 10.37 to 27.36 over the past decade. While the company's 10-year median is 17.77 vs. the industry median of 2.76, iRay Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.76, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRay Group's current ROE % of 12.77% is 363.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on iRay Group and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRay Group's current ROE % is 12.77%, which is 28% below median its own 10-year median of 17.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRay Group stock overvalued right now?
Based on GuruFocus' analysis, iRay Group (SHSE:688301) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥109.99, compared to a current price of ¥88.54 — trading 19.5% below its estimated fair value. The current ROE % is 12.77%, which is 28% below median its 10-year median of 17.77 and 363.5% above the Medical Devices & Instruments industry median of 2.76. iRay Group's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For iRay Group (SHSE:688301), the current ROE % is 12.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRay Group (SHSE:688301) Overvalued in 2026?
Based on GuruFocus' analysis, iRay Group stock appears to be undervalued.
The current stock price of ¥88.54 is trading 19.5% below its estimated GF Value™ of ¥109.99.
GuruFocus considers iRay Group to be Modestly Undervalued.
Key valuation signals for SHSE:688301:
ROE %: 12.77% (28% below median its 10-year median of 17.77)
GF Value™: ¥109.99 vs. price of ¥88.54 (19.5% below fair value)
Industry Position: 363.5% above the Medical Devices & Instruments median (#180 of 796)
No single metric tells the full story. See the SHSE:688301 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688301 has been successfully added to your 
